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Abstract
Inflammatory bowel disease (IBD) is a chronic 
inflammatory condition of the gut characterised 
by alternating periods of remission and relapse. 
Whilst the mechanism underlying this disease is yet 
to be fully understood, old and newer generation 
treatments can only target selected pathways of 
this complex inflammatory process. This narrative 
review aims to provide an update on the most recent 
advances in treatment of paediatric IBD. A MEDLINE 
search was conducted using “paediatric inflamma-
tory bowel disease”, “paediatric Crohn’s disease”, 
“paediatric ulcerative colitis”, “treatment”, “therapy”, 
“immunosuppressant”, “biologic”, “monitoring” and 
“biomarkers” as key words. Clinical trials, systematic 
reviews, and meta-analyses published between 2014 
and 2016 were selected. Studies referring to earlier 
periods were also considered in case the data was 
relevant to our scope. Major advances have been 
achieved in monitoring the individual metabolism, 
toxicity and response to relevant medications in IBD 
including thiopurines and biologics. New biologics acting 
on novel mechanisms such as selective interference with 
lymphocyte trafficking are emerging treatment options. 
Current research is investing in the development of 
reliable prognostic biomarkers, aiming to move towards 
personalised treatments targeted to individual patients.
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Core tip: This narrative review summarises the current 
practice in treating children with inflammatory bowel 
disease (IBD) and explores the new advances and 
future aims. A particular focus of the review are the 
peculiarities of the paediatric age in respect to the 
standard practice in adult patients with IBD. Whilst the 
cause of this condition remains only partly understood, 
a significant proportion of children does not respond to 
the treatment options currently available. Developing 
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new treatments is therefore a key target. Major 
advances have already been achieved in therapeutic 
drug monitoring.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic 
inflammatory condition of the gut characterized by 
alternating periods of remission and relapse[1]. 
It comprises Crohn’s disease (CD), ulcerative colitis 
(UC) and IBD-Unclassified (IBD-U), and its incidence 
has increased steadily worldwide, particularly in 
Western countries[2-4]. The disease affects both children 
and adults, with current estimated prevalence of 
2.6 million people in Europe and 1.2 million in North 
America[5]. Approximately 25% of IBD patients are 
diagnosed before the age of 18[6]. Given that a cure for 
IBD hasn’t been developed so far, treatments currently 
available are mainly aimed to induce and maintain 
remission. Therapeutic options include corticosteroids 
which have shown up to 80% efficacy in inducing 
remission in patients with CD. Other immunomodulators 
used for the treatment of IBD include thiopurines [i.e., 
azathioprine (AZA) and 6-mercaptopurine], metho-
trexate (MTX) and biological treatments such as anti-
tumour necrosis factor (anti-TNFa) therapies like 
infliximab (IFX) and adalimumab (ADA)[5].
CD is characterized by focal, patchy, transmural 
and granulomatous inflammation and it can affect any 
part of the intestinal tract as well as extra-intestinal 
tissue[4]. Peak age of diagnosis of CD is between 12 
and 25[7]. 
Due to its typical onset in the young age and to the 
chronicity of the disease, medical treatment remains 
the cornerstone in CD, with most patients requiring 
lifelong therapy[4]. Whilst for CD surgery is generally 
an option restricted to patients resistant to maximised 
medical treatments or with specific complications, 
approximately 75% of patients with CD will eventually 
undergo surgical resection[4,8]. Nevertheless, according 
to the current epidemiology data available, up to 73% 
of these patients will experience endoscopic recurrence 
of disease at one year post surgery and 22% to 55% 
will have a clinical relapse at five years[8]. 
UC mainly involves the large bowel mucosa, with 
inflammation extending proximally from the rectum 
in a continuous fashion. In approximately 80% of 
children, the disease extent is proximal to the splenic 
flexure, whereas in adults it’s more frequently left 
sided. Prolonged severe inflammation of the colonic 
mucosa is a known risk factor for the development of 
colorectal carcinoma[9]. 
Currently, proven medical treatment of paediatric UC 
is limited to a few options, including amino-salicylates, 
corticosteroids and thiopurines. More recently, anti-TNF 
agents have been established for the management of 
patients with UC who are refractory to conventional 
medical treatment[10]. Choice of therapy is mainly based 
on disease extension and severity of inflammation. Up 
to 25% of the total patients with UC currently require 
a colectomy because of ongoing, severe inflammation, 
unresponsive to medical therapy, or when the disease is 
steroid-dependent[11]. 
When a child is diagnosed with IBD, achieving early 
remission has a positive impact on normal child growth 
and development, long-term remission and quality of 
life, thus reducing the psychological burden[2]. Children 
tend to present with a more aggressive course of IBD, 
therefore immunomodulators and biological treatments 
are used extensively[2]. 
Achieving satisfactory nutritional status and reaching 
growth target should be one of the focuses in paediatric 
IBD. In fact, nutritional concerns are still common in 
children with CD (up to 65%-75% of cases) who are 
often underweight at presentation[3,6,12]. Even in the 
longer term, despite current treatment strategies for CD 
including biologics, short stature and slow growth are 
still encountered in paediatric CD. 
Whilst an early diagnosis is pivotal to minimize 
growth deficiency, the signs of CD onset vary and can 
easily go unnoticed, causing growth deficiency and 
pubertal delay to precede the intestinal manifestations 
of the disease[12].
Poor bone health, delayed puberty, and growth 
failure may go on to complicate these patients’ clinical 
management[2,6,12].
The pharmacokinetics (PK) and pharmacodynamics 
of drugs in children are different from those in adults 
and the approach to paediatric drug dosing needs to be 
based on the physiological characteristics of the child 
and the pharmacokinetic parameters of the drug[13].
Current European Medicines Agency (EMA) and 
United States Food and Drug Administration (FDA) 
guidance recommends that dose selection for paediatric 
studies is based on extensive and detailed prior in-
formation, starting with what has been learnt in adult 
populations[14]. Paediatric pharmacometric approaches 
are increasingly being applied to drugs already in use, 
but that remain unlicensed and off-label in children[14]. 
There are multiple factors contributing towards the 
pathogenesis of IBD, and the whole mechanism is 
yet to be entirely defined in its complexity. Current 
hypotheses suggest the host’s genetic profile, immune 
system and environmental factors such as the gut 
microbiota as possible key factors[3].
IBD may develop from a chain of events involving 
alteration in the microbiome, increase in intestinal 
permeability leading to bacterial translocation, and 
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subsequent activation of the adaptive immune 
response to cause tissue damage (a model known as 
“bacterial penetration cycle hypothesis”)[15]. 
As a result of the uncontrolled activation of the 
mucosal immune system, the pro-inflammatory 
cytokines released cause chronic inflammation of 
the gastrointestinal tract[5]. In consideration of the 
crucial role played by cytokines in the development of 
intestinal inflammation, all current treatments for IBD 
target downstream events in the host inflammatory 
response[15]. 
Given the complexity and heterogeneity of IBD, a 
holy grail of current research is to be able to customize 
therapy to a patient’s predictive biomarker profile, 
in order to personalise treatment and to maximise 
response[11].
Studies in adult patients with CD have shown 
that treatments capable of inducing and maintaining 
endoscopic mucosal healing (MH) have a positive 
impact on the disease course, by reducing the number 
of clinical relapses, hospitalizations and surgical 
interventions[16]. Therefore, the current aim in the 
care of IBD for all ages is achieving intestinal MH, i.e., 
beyond the simple resolution of symptoms[3]. 
Based on this evidence, the strategy of early 
introduction of immunomodulators and biological 
therapies (“top-down”) to induce deep remission (long-
term intestinal healing) is increasingly used in high-
risk paediatric patients (e.g., children with extensive 
disease distribution, severe perianal disease, no 
response to standard medical options, growth re-
tardation and delayed puberty) as an attempt to 
modify the clinical course of the disease by inducing 
and maintaining remission, reducing hospitalizations, 
surgeries, use of corticosteroids, as well as promoting 
growth and pubertal development[3]. 
Based on the recommendations above, the conven-
tional “step up” approach for paediatric CD, based 
on amino-salicylates, corticosteroids, and immuno-
modulators, is increasingly outdated for patients at 
high risk of complicated disease[17,18].
This narrative review aims to summarise the most 
recent advances in treating children with IBD and to 
provide with an overview of the new treatments in this 
field.
LITERATURE SEARCH
A Medline search using the keywords “paediatric 
inflammatory bowel disease”, “paediatric Crohn’s 
disease”, “paediatric ulcerative colitis”, “treatment”, 
“therapy”, “immunosuppressant”, “biologic”, “monitoring” 
and “biomarkers” was carried out.
Retrospective and prospective clinical studies, 
systematic reviews and meta-analyses published 
between 2014 and 2016 were selected for this narrative 
review. Studies conducted earlier were also taken into 
consideration whenever the data outline was considered 
relevant to the scope of the review.
DIET, MICROBIOTA AND FAECAL 
TRANSPLANT
Diet has an impact on the composition of the intestinal 
microbiome and gut immune status and currently 
there is growing evidence that the microbiota has a 
relevant role in the pathogenesis of IBD[15].
“Dysbiosis”, an imbalanced intestinal microbiota 
with pro-inflammatory microorganisms prevailing on 
the protecting ones, has been repeatedly reported in 
patients with IBD[19].
Dietary interventions in children with active CD 
have proved evidence of a link between diet and the 
disease[15]. Exclusive enteral nutrition (EEN) using a 
polymeric formula for 6-8 wk, is the first-line therapy 
to induce remission in children with active CD[20,21]. 
EEN is effective in inducing remission in approximately 
80% of patients, with a clinical remission rate similar 
to corticosteroids[3]. However, as opposed to steroids, 
EEN provides significant nutritional benefit and is 
superior in achieving MH[3]. 
EEN also leads to early MH, and long-term benefits 
of EEN-induced MH are currently being looked into[16]. 
Grover et al[16] conducted a prospective cohort study 
on 54 children with new diagnosis of CD, to evaluate 
the impact of early EEN-induced MH on predicting 
sustained remission (SR) on immunomodulators, 
without need for additional therapy like steroids, 
biologics or surgery. Paediatric CD Activity Index 
(PCDAI), C-reactive protein (CRP) and endoscopic 
assessment at diagnosis were paired with those post 
6 wk of EEN. Complete MH was observed in 33%, and 
near complete in 19%. SR was superior in children 
with complete MH vs those with active endoscopic 
disease at 1, 3 and 5 years of follow-up, therefore 
the authors conclude that following induction of 
remission with EEN, complete MH is superior to clinical 
and biochemical remission in predicting SR over and 
beyond 3 years on maintenance immunomodulators[16] 
(Table 1).
Partial enteral nutrition with allowance of free diet 
hasn’t been proved effective yet. It is unclear whether 
this depends on the supply of specific nutrients within 
the polymeric formula or on the exclusion of dietary 
factors during the course of exclusive polymeric diet[15].
Recent studies have aimed to evaluate which of 
the excluded dietary components in EEN may be 
responsible for the effect, in order to look into ways to 
allow a safe whole food diet[15].
Sigall-Boneh et al[15] validated a dietary intervention 
that allows whole foods but reduces exposure to 
dietary components that have been shown to induce 
inflammation, affect the microbiome and the mucous 
layer, increase gut permeability or the adherence and 
translocation of bacteria in mouse or cell line models. 
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Table 1  Summary of the cohort studies mentioned in the review including reference, study design and population, main results, 
conclusions
Ref. Study design Population Main results Conclusion
Nutrition
Sigall-Boneh et al[15] 
Inflamm Bowel Dis 2014
Prospective cohort 
study
47 patients = 34 children 
+ 13 young adults
Post treatment with 6-wk exclusion diet: 
access to specific foods + 50% of calories from 
polymeric formula
Dietary therapy involving PEN 
with an exclusion diet seems to 
lead to high remission rates in 
early mild-to-moderate luminal 
CD in children and young 
adults
Mean age 16.1 ± 5.6 yr Response in 37 (78.7%)
Remission in 33 (70.2%)
Active CD (PCDAI > 7.5 
or Harvey-Bradshaw 
Index ≥ 4)
Decrease in CRP and ESR
Normalisation of CRP in 70% of patients 
entering remission
Grover et al[16] J Crohns 
Colitis 2016
Prospective cohort 
study
54 children with CD Post EEN: Only complete MH post 
EEN induction predicts more 
favourable SR for up to 3 yr
Age < 16 Clinical remission (PCDAI < 10) in 45/54 (83%)
At least 6 wk EEN Biochemical remission (PCDAI < 10, CRP < 5) 
in 39/54 (72%)
Complete MH in 18/54 (33%)
Nearly complete MH in 10/54 (19%)
SR superior in children with MH vs active 
endoscopic disease:
P 0.003 at 1 yr
P 0.008 at 2 yr
P 0.005 at 3 yr
Thiopurines
Stocco et al[23] World J 
Gastroenterol 2015
Retrospective 
cohort study
12 paediatric patients = 6 
CD + 6 UC
NAT1 genotypes (fast enzymatic activity) were 
associated with reduced TGN concentration
NAT1 genotype affects 
TGN levels in patients 
treated with thiopurines and 
aminosalicylates and could 
therefore influence the toxicity 
and efficacy of these drug
The effect of NAT1 on TGN persists even 1 mo 
after the interruption of the aminosalicylate
No effect of the NAT2 polymorphism was 
observed
Biologics and biosimilars
Sharma et al[7] Inflamm 
Bowel Dis 2015
IMAgINE-1 study Paediatric CD population 
= 192
Strong positive association between serum 
ADA concentration and disease remission/
response to treatment
Positive association between 
serum ADA concentration 
and remission/response 
in paediatric patients with 
moderate/severe CD
Phase-3, 
randomized, 
Higher body weight, baseline CRP, lower 
albumin, previous treatment with anti-TNF 
and presence of anti-IFX antibody were 
associated with increased ADA clearance
Multicentre, 
double-blind
Nuti et al[18] J Crohns Colitis 
2016
Prospective cohort 
study
37 biologic-naïve 
paediatric patients with 
CD
Biological therapy with IFX + AZA was 
effective in achieving MH (based on change in 
PCDAI and SES-CD)
Biologics improve mucosal 
lesions, more effectively if 
given in combination with 
immunomodulators. 
Combination of biologics + 
immunomodulators was more effective than 
biological monotherapy
MH predicts a better disease 
course
Improvement of mucosal lesions at 2 yr 
follow-up was predictive of favourable 
outcomes
Fumery et al[33] J Pediatr 
Gastroenterol Nutr 2015
Retrospective 
population based 
study (EPIMAD 
registry)
27 paediatric patients 
with CD experiencing IFX 
failure
Effectiveness and safety of ADA: Treatment with ADA was safe 
and effective in two-thirds of 
patients with pediatric-onset 
CD and IFX failure
Clinical benefit: 19 (70%) measured by the 
physical global assessment score
Significant decrease in CRP in children 
responding to ADA (9 vs 15 mg/L)
Cumulative probability of failure to ADA 
treatment:
38% at 6 mo, 55% at 1 yr
Primary failure: 8 (30%)
Secondary failure: 5 (26%)
Adverse effects: 11 (40%)
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5473 August 14, 2017|Volume 23|Issue 30|WJG|www.wjgnet.com
Frymoyer et al[38] J Pediatr 
Gastroenterol Nutr 2016
Monte Carlo 
simulation 
analysis 
constructed using 
a published 
population 
pharmacokinetic 
model based on 
data from 112 
children in the 
REACH trial
1000 simulated children Trough IFX concentration > 3 mg/mL was 
achieved at week 14 in 21% for albumin level 
of 3 g/dL vs 41% for albumin of 4 g/dL
Standard IFX maintenance 
dosing in children with CD is 
predicted to frequently result in 
inadequate exposure, especially 
when albumin levels are low.
Dziechciarz et al[34] J 
Crohns Colitis 2016
Systematic review 
of 14 studies
Efficacy and safety of 
ADA I paediatric patients 
with CD
Pooled remission rates: According to low-quality 
evidence based mainly on case 
series, approximately half of 
children with CD on ADA 
therapy achieve remission 
during the first year of the 
therapy with reasonable safety 
profile
At 4 wk: 30% (n = 93/309)
At 3 mo: 54% (n = 79/145)
At 4 mo: 45% (n = 18/40)
At 6 mo: 42% (n = 146/345)
At 8 mo: 57% (n = 20/35)
At 12 mo: 44% (n = 169/383)
Primary non-responders: 6% (13/207)
Severe adverse events: 12% (69/599)
Conrad et al[39] Inflamm 
Bowel Dis 2016
Observational, 
single-centre, 
prospective cohort 
study
21 paediatric patients (16 
CD, 5 UC) with refractory 
IBD who had previously 
failed anti-TNFa therapy
Clinical response post treatment with 
vedolizumab: 
6/19 (31.6%) at week 6
11/19 (57.9%) at week 22
Steroid-free remission in 1/20 (5%) at week 6, 
3/20 (15%) at week 14 and 4/20 (20%) at week 
22.
Singh et al[44] Inflamm 
Bowel Dis 2016
Retrospective 
review on the 
experience with 
vedolizumab
52 paediatric patients 
with IBD, 90% of whom 
had failed ≥ 1 anti-TNF 
agent
Week 14 remission rates: 76% for UC, 42% for 
CD, 80% of anti-TNF naïve IBD
Clinical response to 
vedolizumab in children with 
moderate/severe CD increases 
from week 14 to week 22 
Week 22 remission rates:
100% anti-TNF naïve vs 45% anti-TNF exposed
Sieczkowska et al[46] J 
Crohns Colitis 2016
Prospective cohort 
study
39 paediatric patients: 32 
with CD, 7 with UC
Clinical remission: No differences in treatment 
efficacy, after switching from 
IFX originator to its biosimilar88% for CD
Children were switched 
from IFX originator to its 
biosimilar
57% for UC
All patients had PCDAI ≥ 
25 at the time of switching
Thalidomide
Lazzerini et al[49] JAMA 
2013
Double-
blind, placebo-
controlled, 
randomized 
clinical trial
56 padiatric patients with 
active CD, randomised to 
receive either thalidomide 
or placebo
Clinical remission achieved by 13/28 (46.4%) 
of the children treated with thalidomide vs 
3/26 (11.5%) of those who received placebo 
(P = 0.01)
Thalidomide compared with 
placebo resulted in improved 
clinical remission at 8 wk of 
treatment and longer-term 
maintenance of remission.Almost all had not 
responded to thiopurines 
and 35% had not 
responded to biologics
Responses were not different at 4 wk, but 
greater improvement was observed at 8 wk in 
the thalidomide group [75% response in 13/28 
(46.4%)] vs 3/26 (11.5%)(P 0.01)
Of the non-responders to placebo who began 
receiving thalidomide, 11 of 21 (52.4%) 
subsequently reached remission at week 8 
(P = 0.01). 
Overall, 31 of 49 children treated with 
thalidomide (63.3%) achieved clinical 
remission
Mean duration of clinical remission in the 
thalidomide group was 181.1 wk vs 6.3 wk in 
the placebo group (P < 0.001). 
Lazzerini et al[50] Inflamm 
Bowel Dis 2015
Multicenter, 
double-blind, 
placebo-
controlled, 
randomized 
clinical trial
26 paediatric patients 
with active UC, 
randomised to receive 
thalidomide or placebo
Clinical remission at week in 10/12 (83.3%) of 
the children treated with thalidomide vs 2/11 
(18.8%) of those who received placebo 
(P = 0.005)
Thalidomide compared with 
placebo resulted in improved 
clinical remission at 8 wk of 
treatment and in longer term 
maintenance of remission.All patients had had 
thiopurines and 35% 
had received prior IFX 
treatment
Of the non-responders to placebo who were 
switched to thalidomide, 8 of 11 (72.7%) 
subsequently reached remission at week 8 
(P = 0.01)
Clinical remission in the thalidomide group 
was 135 wk compared with 8 wk in the 
placebo group (P < 0.0001). 
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They recruited 47 patients including 34 children and 
13 young adults with active disease, who were treated 
with a 6-wk exclusion diet that allowed access to 
specific foods and up to 50% of dietary calories from a 
polymeric formula. 
The diet consisted in elimination of or reduction 
in animal fat, dairy products, gluten, and emulsifiers 
whereas fibre from fruits and vegetables was allowed. 
Clinical response was observed in 78.7% and remission 
in 70.2%, alongside improvement in CRP (normalized 
in approximately 70%) and ESR. On the basis of 
these results, the Authors recommend the use of 
this elimination diet in patients with mild-moderate 
disease, as it allows access to specific foods improving 
palatability and compliance[15] (Table 1).
So far, efficacy of microbiome-based therapies like 
probiotics or antibiotics has been limited in IBD[19]. 
Nevertheless, the recent focus on dysbiosis as a 
plausible key factor in IBD pathogenesis, has led to a 
growing interest in faecal microbiota transplantation 
(FMT) as a novel potential treatment option in IBD. 
FMT is the administration of faecal material from 
a donor into the intestinal tract of a recipient, with 
the aim to change the microbiota composition and 
restore mucosal health. Over the past few years, 
FMT has been used successfully for the treatment of 
recurrent Clostridium difficile infection (CDI) (efficacy 
of 80%-95%), and is now being evaluated in other 
diseases possibly driven by the microbiota, including 
IBD[19].
There are several studies and case reports on the 
use of FMT in UC, but only two randomized control 
studies published to date[19,20,22].
The success rate of FMT in treating UC has been much 
more limited (clinical remission in 35%) in respect to its 
success in treating recurrent CDI. However, studies so 
far have been small and heterogeneous, therefore clear 
conclusions are difficult to make[19]. 
Even less data is available for FMT in CD, with only 
isolated cases or heterogeneous small series reporting 
overall clinical remission in 60%-75%[19].
At present, evidence on FMT in IBD is not strong 
New treatments
Tew et al[11] 
Gastroenterology 2016
Retrospective 
analysis of two 
cohorts: 1. phase 2 
placebo-controlled 
trial;
110 patients with UC 
(cohort 1) and 21 patients 
including UC and 
controls (cohort 2)
Increased expression of T-cell associated genes 
in baseline biopsies of anti-TNF naïve patients 
who achieved clinical remission in response to 
etrolizumab
Levels of GZMA and ITGAE 
mRNAs in colon tissues can 
identify patients with UC who 
are most likely to benefit from 
etrolizumab
2. observational 
study at a separate 
site 
Patients with high colonic integrin aE 
expression showed greater benefit
GZMA is a promising 
biomarker for etrolizumab 
response
GZMA expression was different post-
treatment
Sandborn et al[51] N Engl J 
Med 2016
Double-
blind, placebo-
controlled, phase-2 
trial 
197 adult patients with 
moderate-severe UC
Clinical remission at 8 wk: Ozanimod at a daily dose of 1 
mg resulted in a slightly higher 
rate of clinical remission of UC 
than placebo
16% of patients who received 1 mg of 
Ozanimod vs 14% who received 0.5 mg vs 6% 
of those who received placebo
Clinical remission t 32 wk:
21% vs 26% vs 6% respectively
Drop in absolute lymphocyte count at week 8:
49% from baseline in the group who received 
1 mg of Ozanimod
32% from baseline in the group who received 
0.5 mg
Allez et al[52] Gut 2016 Randomised, 
double-blind, 
parallel group trial
78 adult patients with CD No significant difference in change in CDAI 
from baseline to week 4, between NKG2D 
group and placebo group
A single s.c. dose of 2 mg/kg 
anti-NKG2D did not reduce 
disease activity at week 4 vs 
placebo, but the difference was 
significant at week 12
Age 18-75 Significant difference in change in CDAI at 
week 12 (delta CDAI -55, P ≤ 0.1) between 
NKG2D group and placebo group
Disease duration ≥ 3 mo Significant improvement noted in the non-
failure to biologic subgroup treated with anti-
NKG2D from week 1
CDAI 220-450
CRP ≥ 10 mg/L
Endoscopic evidence of 
inflammation
ADA: Adalimumab; CD: Crohn’s disease; CDAI: Crohn’s disease activity index; CRP: C-reactive protein; EEN: Exclusive enteral nutrition; GZMA: 
Granzyme A; IFX: Infliximab; ITGaE: Integrin aE gene; MH: Mucosal healing; NAT: N-acetyl transferase; PCDAI: Paediatric Crohn’s disease activity index; 
PEN: Partial enteral nutrition; s.c.: Subcutaneous; SES-CD: Simple Endoscopic Score for Crohn's Disease; SR: Sustained remission; TGN: Thioguanine 
nucleotides; UC: Ulcerative colitis.
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enough to recommend its use as part of routine 
treatment. Preliminary results are promising and more 
studies are needed to define the best indications, 
optimal timing, frequency, mode of delivery, and the 
most appropriate donor for each patient[19].
AMINOSALYCILATES
5-aminosalicylic acid (mesalazine, 5-ASA) acts 
topically on the gastrointestinal mucosa, with minimal 
systemic effect. Even though its exact mechanism of 
action is yet to be understood in its complexity, the 
pathways that are known to be involved include the 
blockade of IL-1 production and TNF-α receptor, the 
inhibition of cyclooxygenase and 5-lipoxygenase, and 
the blockade of the pro-inflammatory prostaglandin E2 
and leukotrienes. On top of the inhibition of multiple 
inflammatory pathways and the suppression of the 
nuclear factor kappa B as a main result, amino-
salicylates also possess potent anti-oxidant and free-
radical-scavenger properties[4]. Amino-salicylates 
are mainly used in the induction and maintenance of 
remission in UC[23].
In CD, their use is no longer recommended in 
view of limited efficacy. However, there are studies 
suggesting a possible role in the postoperative main-
tenance of remission, as well as in the subgroup of 
children with mild, localised ileal disease. In addition, 
adult studies suggest a protective role of 5-ASA in IBD 
against colon cancer in patients with colonic location[23].
Given that sulfasalazine is not tolerated in 30%-40% 
of patients, particularly slow acetylators, the use of its 
therapeutically active component 5-ASA has led to the 
development of new formulations, that deliver higher 
concentrations of 5-ASA without the dose-limiting 
side effects of sulfasalazine. A wide range of these 
formulations is available and comprises pH-dependent 
release coated drugs (targeting the ileum), time-
dependent release micro-granules enclosed within a 
semi-permeable membrane of ethyl-cellulose (released 
in the whole small and large intestine), and azo-bonded 
formulations released throughout the colon[4].
CORTICOSTEROIDS
Corticosteroids are used as first-line therapy for 
induction of remission in UC, particularly in patients with 
non-response to 5-ASA or with severe presentation, 
as well as to induce remission in CD when EEN is not 
possible[3,9,24]. 
The mechanism of action of corticosteroids consists 
in inhibiting protein synthesis and transcription, 
which ultimately results in down-regulation of pro-
inflammatory cytokines, such as NF-kappa B, TNF-α, 
interleukin-1 and interleukin-6[9].
Clinical remission rates for CD are up to 80%, 
similarly to EEN, whereas MH rates are significantly 
lower[3]. Corticosteroids improve rapidly and effectively 
the signs and symptoms of disease in CD, however 
they are ineffective, and inappropriate, for maintenance 
therapy[17].
In children with moderate-severe active luminal CD, 
oral prednisolone is given at 1 mg/kg, with a maximum 
of 40 mg/d, followed by a weaning course over 8-10 
wk. Intravenous steroids may be initially needed for 
severe disease and include methylprednisolone (1-1.5 
mg/kg, maximum: 60 mg/d) and hydrocortisone (2-4 
mg/kg per dose, maximum 100 mg/dose, four times a 
day)[3]. 
Adverse effects like adrenal suppression, growth 
failure, cosmetic and behavioural effects, are dependent 
on dose and duration[3]. 
Budesonide (maximum of 12 mg/d, followed by 
weaning course over 2-4 wk) is a topically acting 
corticosteroid with high first pass hepatic metabolism, 
which reduces the likelihood of adverse effects[3,9]. 
Budesonide is particularly recommended for patients 
with mild to moderate CD involving the distal ileum and/
or right colon, as it has been shown to be non-inferior 
to conventional oral steroids for inducing remission in 
this specific group. It has also proved to be an effective 
therapeutic option as enema formulation for distal UC[9].
There are currently three formulations of bude-
sonide: two standard formulations including a controlled-
release capsule and a pH-dependent capsule both 
designed to target the ileum and right colon; and a more 
recent Budesonide-MMX® capsule that releases the 
drug throughout the entire colon[9].
THIOPURINES
Thiopurines are purine analogues used for the main-
tenance of disease remission in patients with CD and 
UC; they include the prodrug AZA and the antime-
tabolite 6-MP[25,26].
AZA is non-enzymatically degraded to 6-MP which is 
then metabolised to its active component, 6-thioguanine 
nucleotide (6-TGN)[8]. 6-TGN inhibits the proliferation of 
T and B lymphocytes, which results in a decrease in the 
numbers of cytotoxic T cells and plasma cells[8].
These dugs are able to block the rapid cell proli-
feration involved in inflammatory processes, which 
results in immunosuppression[26].
For the treatment of IBD, thiopurines are used 
at relatively low dosages, so their anti-inflammatory 
effect is mainly produced by the inhibition of the 
small GTPase Rac1, leading to apoptosis of activated 
T-lymphocytes. When given at higher dosages, as in 
oncological treatments, thiopurines mainly inhibit DNA 
synthesis[26].
Thiopurines are steroid sparing agents and have 
been proven effective maintenance treatment in 
paediatric IBD: studies have shown significantly lower 
cumulative steroid doses and relapse rates at 18 mo 
in children on 6-MP compared with placebo (9% vs 
47%) as well as a reduced need for surgery in CD[3,23]. 
Recommended doses are 1.0 to 2.5 mg/kg per day for 
AZA and 1 mg/d for 6-MP[25].
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Thiopurines are also used effectively to maintain 
surgically-induced remission in CD, even though a 
systematic review by Gordon et al[8] pointed out that 
the results for efficacy outcomes between thiopurines 
and 5-ASA in this group of patients are uncertain.
Testing the activity of the enzyme thiopurine-S-
methyltransferase (TPMT) is recommended to guide 
thiopurine dosing avoiding adverse events[26].
Genetic polymorphisms in the TPMT gene are 
associated with a reduced enzymatic activity and an 
increased production of the active metabolites TGNs[23].
A large prospective study with 1000 individuals 
established TPMT activity reference intervals, with 
normal activity associated with a level ≥ 25 nmol/h 
per gram Hgb[27].
According to the current data available, 1 in 300 
patients have a very low to absent TPMT activity 
(homozygous mutant TPMT), 11% have intermediate 
TPMT activity (heterozygous) and 89% have normal to 
elevated activity (homozygous wild type TPMT)[27].
The use of thiopurines is limited by an extensive 
spectrum of adverse events in up to almost half of 
patients, particularly within the first twelve months 
of treatment. Adverse effects include myelotoxicity, 
hepatotoxicity, pancreatitis and gastrointestinal 
complaints[26].
Measuring TPMT activity levels (phenotype) or 
determining TPMT genotype before initiating thiopurine 
therapy, is recommended by the FDA to limit the 
likelihood of side effects[27]. However, it still remains 
possible to develop significant myelotoxicity despite 
normal TPMT activity.
The use of TPMT activity and 6-TGN level monitoring 
has the potential to avoid nearly a quarter of episodes 
of myelosuppression[27]. In addition, 6-TGN monitoring 
is helpful to detect non-compliance, under-dosing, and 
drug resistance or refractory states[27].
Blood levels of thiopurine metabolites correlate 
with the efficacy and toxicity of these drugs as 
follows: TGN levels higher than 235 pmol/8 × 108 
red blood cells reflect an adequate therapeutic level, 
whereas methyl mercaptopurine nucleotides levels 
above 5700 pmol/8 × 108 red blood cells are indicative 
of hepatotoxicity[23].
AZA or 6-MP can be started at the full recommended 
dose of 2-2.5 mg/kg per day or 1-1.5 mg/kg per day, 
respectively, in patients with normal to high TPMT 
activity level. Patients with an intermediate TPMT 
activity should start, instead, with a daily dose reduced 
by 30%-70%. Alternative therapy should be offered 
to individuals with low or absent TPMT activity, or they 
should be started at 10% of the suggested dosing, 
given three times per week[27].
The results of a recent retrospective study by 
Benmassaoud et al[27] evaluating the safety and 
efficacy of starting thiopurines at low dose vs full dose 
in adult patients with CD and normal TPMT, suggest 
that AZA should be started on full dose in patients 
with normal TPMT, rather than starting on a lower 
dose and increasing slowly. This is mainly due to the 
fact that patients with normal TPMT level may still 
be exposed to side effects that are unrelated to the 
enzymatic activity[27]. Overall, almost half of the adults 
treated with thiopurines discontinue their treatment 
due to ineffectiveness or intolerance[26]. It has been 
hypothesized that prescribing thioguanine (TG) therapy 
instead of AZA/6-MP reduces the release of potentially 
toxic metabolites, as its metabolism is less complex 
with a more direct conversion to the therapeutically 
active metabolite 6-TGN[1]. 
In a systematic review, Meijer et al[1] describe how 
TG therapy can represent a valuable option in adult IBD 
patients intolerant to conventional thiopurine therapy, 
with efficacy in 65% of patients and short term adverse 
events in 20%. However, TG is currently only used as 
experimental or rescue therapy and should not be used 
outside highly controlled situations[1]. Thiopurines and 
amino-salicylates are often used in combination in the 
treatment of IBD[23]. 
An increase in mean TGN blood levels has been 
reported in patients on concomitant treatment with 
thiopurines and 5-ASA. Moreover, a higher rate of 
myelotoxicity was observed in this group of patients 
compared with those treated with the thiopurine 
alone[22]. A plausible explanation comes from in vitro 
studies showing that amino-salicylates and their 
metabolites can inhibit the activity of TPMT, even 
though this observation has not been yet replicated in 
vivo[23].
The enzymes N-acetyltransferases (NAT1 and 
NAT2, EC 2.3.1.5) are responsible for the N-acetylation 
of multiple drugs including the amino-salicylates. 
Subjects are classified as rapid, intermediate or slow 
acetylators based on the activity of NAT1 and NAT2 
that is genetically determined[23]. 
Stocco et al[23] evaluated the variation of the 
level of TGN after 5-ASA cessation and the role of 
genetic polymorphisms of NAT 1 and 2, in a group of 
12 children recruited at two tertiary level paediatric 
gastroenterology units (6 CD and 6 UC) (Table 1).
Rapid acetylators with NAT1 genotypes were found 
to have reduced TGN concentration, and the effect of 
NAT1 activity on TGN persisted up to one month after 
discontinuation of the 5-ASA. NAT2 polymorphism, 
instead, did not produce any effect. These results, 
though limited by the small number of patients, show 
that the NAT1 genotype affects TGN levels in patients 
treated with thiopurines and 5-ASA and it may 
therefore impact on the efficacy and toxicity of these 
drugs[23] (Table 1).
MTX
MTX, a dihydrofolate reductase inhibitor, has long been 
used effectively to treat rheumatoid arthritis until it 
was brought into the field of IBD to treat patients with 
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refractory CD. Nowadays, it has become one of the 
principal alternatives to thiopurines as maintenance 
treatment[28,29].
Efficacy of MTX, given at 15 mg/m2 once a week 
for a maximum of 25 mg/wk subcutaneously, is 
reported as 50%-80% by retrospective cohort studies 
in children who failed to respond or were intolerant to 
thiopurines[3]. MTX is a first-line treatment option in 
patients who have concomitant inflammatory arthritis 
and it represents a valuable alternative to maintenance 
treatment with anti-TNF[3,29]. Adverse events associated 
with MTX include flu-like symptoms, transaminitis and, 
less frequently, myelosuppression, which may require 
dosage adjustment or drug withdrawal[3]. Nausea 
and vomiting have been reported in 11%-24% of 
patients, the majority of whom respond to antiemetic 
medication. Significant hepatocellular liver disease is 
rare. Contraception is essential[3]. 
Systematic reviews performed by MacDonald JW 
and by Patel et al[29] to assess the efficacy and safety 
of MTX for the treatment of active refractory CD in 
adults, show that intramuscular MTX is effective in 
inducing remission and acts as a steroid sparing agent 
allowing complete withdrawal from steroids[28,30,31]. 
Lower dose oral MTX does not appear to provide 
any significant benefit in respect to placebo or active 
comparator[28,31-33]. Though limited by the small size of 
the studies analysed, this review could not identify any 
additional benefit from combining MTX and IFX over 
IFX monotherapy[28,31]. 
BIOLOGICS AND BIOSIMILARS
TNF is produced by macrophages, adipocytes, fibroblasts 
and T cells and acts as a pleiotropic, pro-inflammatory 
cytokine by triggering a cascade of events that lead to 
tissue damage[5,7]. 
IFX, ADA and other anti-TNF agents act by su-
ppressing downstream pathways mediated by TNF 
including angiogenesis, increase in T-helper cell 1 (Th1) 
cytokine production (interleukin-12 and interferon-γ), 
death of intestinal epithelial cells and T-cell resistance 
to apoptosis[5]. 
Anti-TNF medications are able to achieve and 
maintain MH, with growing evidence of a change in the 
natural history of the disease. Importantly, as opposed 
to a few years ago when clinical response and remission 
were the main goals in treating patients with IBD, MH 
has recently been emphasized as a stronger therapeutic 
goal, as it predicts sustained clinical remission. 
Therefore, a new concept of “deep remission” has 
been coined, including MH alongside clinical and/or 
biochemical remission[18]. Also thiopurines and EEN 
with polymeric diet have been previously reported to 
achieve MH, albeit less rapidly and to a lower degree 
than biologics[18]. According to the studies performed 
on adult populations, scheduled maintenance therapy 
with IFX maintains MH in up to 68% of patients, and 
the subgroup of patients achieving MH show decreased 
rate of surgeries and hospitalizations[18].
IFX
IFX is a chimeric monoclonal antibody and was the 
first biologic approved for the treatment of moderate 
to severe paediatric CD[34]. The advent of biological 
therapies has drastically modified the treatment 
strategies and disease course of IBD in children and the 
role of IFX and ADA in the management of paediatric 
IBD was recently updated in the Consensus guidelines 
of ECCO/ESPGHAN[6]. In CD, anti-TNF therapies are 
currently well established in moderate to severe disease 
with lack of response to conventional therapy including 
corticosteroids and immunomodulators, or with con-
traindications or intolerance to it[34]. Anti-TNF agents are 
also used as a primary induction option for children with 
active perianal fistulising disease, in combination with 
targeted surgical intervention, as well as in children at 
risk of poor outcomes (top-down treatment)[3,20]. One 
year response and remission rates for IFX in luminal 
disease are reported as up to 90% and 55%-60% 
respectively[35,36]. Repeated administration of IFX can 
lead to immunogenicity in some patients, with possible 
loss of efficacy and delayed-type hypersensitivity[34]. 
A low proportion of children with CD (10%-25%) are 
primary anti-TNF non-responders, i.e., they fail to 
respond after the 6 wk induction course. More commonly, 
however, the formation of antibody against the drug 
over time can result in secondary loss of response. 
Concomitant treatment with either thiopurines or 
MTX has been shown to contain this process[3]. A key 
step in managing IFX therapy over the more recent 
years is the increasing availability of therapeutic drug 
monitoring (TDM), that has improved response rates 
and has become a most effective tool for the manage-
ment of secondary failure to IFX[37].
Increasing evidence has shown that trough IFX 
concentrations < 3 mg/mL during maintenance 
therapy are associated with treatment failure. Also, 
children with lower albumin levels have higher IFX 
clearance and lower drug exposures[38]. Therefore, 
standard IFX maintenance dosing of 5 mg/kg every 
8 wk may not be adequate for all children with CD 
to achieve sufficient concentration level and thus 
minimise loss of response (Table 1). Unfortunately, 
patients who don’t respond to one anti-TNF are more 
likely to also fail a second agent[39]. Researchers 
hypothesized that a combination therapy of an anti-
TNF antibody and another immunomodulator (i.e., 
thiopurines or MTX) will increase the efficacy and 
reduce the risk of loss of response[40].
There are several adult trials showing higher 
treatment efficacy (especially for induction of remission) 
in patients receiving combination therapy. In particular, 
concomitant immunomodulators increase IFX levels 
and reduce immunogenicity[40]. On the other hand, 
combination therapy in adults exposes patients to the 
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individual toxicity of both drugs and also seems to 
increase the risk of malignancy[40]. In paediatric IBD, the 
safety of combined treatment has been questioned after 
several cases of hepatosplenic T-cell lymphoma (HSTCL) 
in young patients with IBD so treated were reported. 
Nevertheless, a review by Cozijnsen et al[40] points 
out that almost all studies in paediatric patients with 
IBD have failed to prove increased benefit from 
combination therapy compared to monotherapy. Given 
the controversial aspects above, the Authors suggest to 
target the use of combination therapy to children with a 
high risk of serious disease-related complications, such 
as growth delay, stricturing or fistulising CD phenotype, 
or panenteric CD[40].
In order to assess the risk of malignancies asso-
ciated to immunosuppressive treatments in IBD, a 
retrospective multinational survey of malignancy and 
mortality in paediatric IBD was conducted over a 6 
years period (2006-2011) by the Porto Pediatric IBD 
working group of ESPGHAN[41]. The most common 
malignancies identified were hematopoietic tumors 
(n = 11), of which 3 were HSTCL and 3 Ebstein-Barr 
virus-associated lymphomas[41]. These 6 patients 
had all been treated with thiopurines until diagnosis 
of cancer and only 1 patient had also received 3 IFX 
infusions, 5 years before the diagnosis of cancer[41]. All 
3 patients who developed HSTCL were males and had 
exposure to thiopurines ranging from 32 to 108 mo; 
none of them received a biologic[41].
ADA
ADA is a fully human IgG1κ monoclonal antibody which 
is similar to IFX in the mode of action, but it differs 
from it as the mouse-derived sequence is removed, in 
order to reduce the immunogenic reactions induced by 
chimeric antibodies[23,34]. ADA is therefore to consider 
as an alternative treatment option in patients who 
have lost response or are intolerant to IFX, or in some 
primary non-responders to IFX[34]. 
ADA was recently approved in Europe and the 
United States for the treatment of paediatric patients 
with CD, based on the results from the IMAgINE-1 
study[7,42,43]. 
IMAgINE-1 study is a phase-3, randomized, double-
blind study conducted by Sharma et al[7] aimed to 
analyse the PK of ADA in a paediatric CD population (n 
= 192), and to evaluate the effect of various factors, 
including demographics (body weight, sex), laboratory 
measurements (CRP, albumin), previous IFX use, 
concomitant immunomodulators, and baseline PCDAI, 
on ADA PK in paediatric patients with moderate-to-
severe CD (Table 1). Furthermore, the relationship 
between serum ADA concentration and remission/
response was explored[24]. 
Trough serum ADA (measured at 5 time points from 
baseline up to 52 wk) and serial anti-ADA antibody 
measurements were performed. The study confirmed 
a strong positive association between serum ADA 
concentration and clinical remission/response to 
treatment[24]. Higher body weight, baseline CRP, and 
lower baseline albumin levels were associated with 
greater clearance of ADA (lower trough levels)[7]. 
Previous treatment with other anti-TNF therapy, 
presence of antibodies to previous IFX therapy, and 
absence of concomitant use of immunomodulators 
were also associated with increased clearance of 
ADA[7]. According to the published experiences from 
tertiary centres, in anti-TNF antibody naiive children 
the 1 year remission rate for ADA is 45%[42], and its 
efficacy has been documented in nearly two-thirds of 
patients who failed IFX[33]. A retrospective study was 
conducted by Fumery et al[33] who used the population-
based EPIMAD registry to evaluate the effectiveness 
and safety of ADA in children with CD experiencing IFX 
failure (Table 1).
Twenty-seven children with CD who received ADA 
before 18 years because of IFX failure or intolerance 
were included. Clinical response measured by the 
physician global assessment score after a median 
follow-up of 16 (8-26) mo was observed in 19 patients 
(70%). Cumulative probability of failure to ADA 
treatment at 6 mo and 1 year was 38% and 55%, 
respectively. Overall, the results from this population-
based cohort of paediatric-onset CD with IFX failure 
show that treatment with ADA was safe and effective 
in two-thirds of patients. More specifically, ADA was 
effective in 100% of children intolerant to IFX, 68% 
of children with secondary failure to IFX, and only 
25% of children with primary failure to IFX[33]. A 
systematic review on the same topic was performed 
by Dziechciarz et al[34]. Who assessed the published 
evidence on the efficacy and safety of ADA for CD in 
children (Table 1).
Randomised controlled trials and observational 
studies (cohort studies, case series of more than 
5 patients) were included. A total of 14 studies (1 
randomised controlled trial, 13 case series), altogether 
including 664 patients (age range 1.9-21 years) were 
available for analysis. The pooled remission rates were: 
30% at 4 wk, 42% at 6 mo and 44% at 12 mo. Of the 
total patients, 6% were primary non-responders and 
12% had severe adverse events reported. However, 
studies differed with respect to patients’ characteristics, 
including percentage of IFX-naïve patients, disease 
duration, disease localisation, ADA doses, treatment 
duration, and follow-up period[34].
The Authors’ conclusion, though limited by the 
low-quality evidence based mainly on case series, is 
that approximately half of the children with CD on 
ADA therapy achieve remission during the first year of 
treatment with reasonable safety profile[34]. 
Vedolizumab
Vedolizumab is a recent biologic treatment, approved 
for adult patients with IBD in 2014. It is an anti-integrin 
therapy that blocks the a4b7 integrin receptor molecule 
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present on the surface of lymphocytes, and thus inhibits 
the migration of intestinal T-lymphocytes into the 
tissue[39,44,45]. As this mechanism of action is restricted 
to the gastrointestinal tract, the risk of systemic 
immunosuppression (i.e., infections and malignancies) 
seen with other IBD therapies is mitigated[39]. 
Its predecessor, natalizumab, acts with a non-
specific binding to the a4 chain which causes 
interference with the lymphocyte trafficking in the 
central nervous system and led to the concern for 
reactivation of John Cunningham (JC) virus and 
subsequent development of progressive multifocal 
leukoencephalopathy (PML)[45]. Vedolizumab, being gut 
specific, does not interfere with immune surveillance 
in the central nervous system, therefore there is no 
risk of PML as assessed by the placebo-controlled 
GEMINI studies[44]. Anti-adhesion therapy appears to 
have a favourable safety profile, though the experience 
in children is still extremely limited[17]. Due to its 
mechanism of action of targeting gut-specific T-cell 
interactions, it is thought that Vedolizumab may not 
sufficiently treat the extra-intestinal manifestations of 
IBD. A dual therapy with therapeutic doses of immune-
suppressants may therefore be needed to treat extra-
intestinal manifestations[39]. So far, Vedolizumab has 
been particularly effective amongst UC patients, with a 
clinical response rate of 50% during induction[39]. Whilst 
the use of Vedolizumab has been approved for the 
treatment of CD and UC in adults, there is increasing 
off-label use in paediatric IBD[44].
Singh et al[44] conducted a retrospective review 
to describe the experience with Vedolizumab in 52 
children with IBD (58% CD and 42% UC) at 3 tertiary 
IBD centres and to examine predictors of remission. 
Ninety percent of the patients had failed at least one 
anti-TNF agent. Week 14 remission rates for UC and 
CD were 76% and 42%, respectively (P < 0.05). At 
week 4, eighty percent of anti-TNF-naive patients were 
in remission. At week 22, anti-TNF-naive patients had 
higher remission rates than those previously exposed 
to anti-TNF (100% vs 45%, P = 0.04). There were no 
safety concerns.
These results support Vedolizumab as an effective 
and safe treatment in children with IBD, with UC 
patients experiencing earlier and higher rates of 
remission than children with CD. Also, the data 
reviewed shows that anti-TNF-naive patients had higher 
remission rates compared to those with previous anti-
TNF exposure[44].
Conrad et al[39] conducted an observational single-
centre prospective cohort study aimed to determine 
the impact of Vedolizumab on clinical response and on 
achieving steroid-free remission over 22 wk of therapy. 
They recruited 21 children with refractory IBD (16 with 
CD), who had previously failed anti-TNF therapy.
Clinical response was observed in 31.6% and 
in 57.9% by week 6 and by week 22, respectively. 
Steroid-free remission was seen in 1 patient at week 
6 and in 4 (20%) at week 22. No infusion reactions 
were observed. Vedolizumab was discontinued in 2 
patients because of severe colitis, requiring surgical 
intervention[39]. These results, though limited by the 
small sample size, describe a number of children with 
severe disease who achieve clinical response in the 
first 6 wk and a further increase in remission rate by 
week 22[39]. Overall, the data currently available on 
Vedolizumab from adult and paediatric studies suggests 
its use as an option to achieve clinical improvement in 
the most severe paediatric IBD patients (both CD and 
UC). 
Biosimilars 
Biosimilars are defined as biological agents that are 
highly similar to another reference drug already 
authorized for use[37,46]. This definition also implies that 
the quality, safety and efficacy of the biosimilar should 
not be affected by any molecular and/or structural 
dissimilarities or any potential differences in the 
underlying mechanisms[37].
Despite keeping the same aminoacid sequence 
as their reference drug, biosimilars end up being a 
different final product due to manufacturing process 
(including cell line, growth condition and purification 
processes), storage and transport, and subsequent 
various post-translational modifications (e.g., glyco-
sylation, phosphorylation, sulfation)[37]. Therefore, 
some uncertainty still exists regarding the exact 
drug efficacy, immunogenicity and pharmacology of 
biosimilars in IBD.
In 2013, the EMA authorized two IFX biosimilars, 
based on two randomized trials on CT-P13 (clinical 
development name for the biosimilar of Remicade): 
Remsima (Celltrion Inc., Incheon, South Korea) and 
Inflectra (Celltrion Inc., Hospira UK Ltd). Because 
both trials showed equivalent efficacy, tolerance and 
safety, EMA extended the approval to all indications 
for which the reference product is labelled, including 
both adult and paediatric CD and UC[37,46]. At present, 
a number of IFX biosimilars are licensed for treatment 
of CD and UC also in the paediatric population.Cost 
containment remains one of the predominant reasons 
for development of biosimilars, with a reduction in 
costs of anti-TNF therapy for IBD by up to 70%[37].
Sieczkowska et al[46] conducted a prospective study 
on 32 children diagnosed with CD and 7 children with 
UC at 3 academic hospitals in Poland; these patients 
were switched from IFX originator to its biosimilar 
(Remsima) (Table 1). Analysis of biosimilar efficacy 
revealed rates of clinical remission of 88 and 57% for 
CD and UC patients, respectively, so, in conclusion, 
switching from IFX originator to its biosimilar was a 
safe option in this cohort and after the switch, the 
biosimilar was just as effective as the originator[46].
To date, preliminary results on CT-P13 in IBD are 
only available from small post-marketing registries 
and case series with a relatively short-term follow-
up period. Although this data suggests comparable 
efficacy and safety to IFX, more robust post-marketing 
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studies and pharmacovigilance are warranted to 
evaluate the bioequivalence of CT-P13 in the coming 
years[37]. In Europe, at present, in order to switch 
patients with IBD from IFX originator to its biosimilar, 
the supervision of the treating physician and the 
patient’s consent are both required[46].
THALIDOMIDE
Thalidomide is an immunosuppressant drug used 
rarely in the treatment of refractory CD and UC[47]. 
Its mechanism of action includes several pathways 
such as inhibition of TNF, IFN-γ and IL-12, stimulation 
of IL-4 and IL-5 production and, more broadly, a shift 
in the pattern of lymphocyte cytokine from a Th1 
(IFN-γ, IL-12) to Th2 (IL-4, IL-5) type[5]. Thalidomide 
also interferes with integrin expression, decreases 
circulating helper T-cells and inhibits angiogenesis[5]. 
After its suspension due to major teratogenic effects, 
thalidomide has been more recently re-introduced 
under FDA approval as an effective treatment for 
multiple myeloma and severe erythema nodosum 
leprosum. It is also extensively used off-label for 
immune-mediated and neoplastic conditions like discoid 
lupus erythematosus, erythema nodosum leprosum, 
Behcet’s syndrome, aphthous stomatitis, juvenile 
idiopathic arthritis, brain tumors, graft-vs-host disease 
and IBD[5,18,48]. 
Thalidomide is used infrequently in the management 
of paediatric CD, nevertheless it represents a helpful 
option in treating children who lose response to one or 
more conventional agents such as thiopurines, MTX, 
and anti-TNF[48].
Thalidomide (administered from 50 to 400 mg/d 
in adults and 1.5 to 2.5 mg/kg per day in children[47]) 
has been shown to induce clinical remission and 
possibly MH[48]. A systematic review by Yang et al[5] 
selected twelve studies (2 RCTs and 10 case series) 
where thalidomide was used to induce remission in 
248 patients with IBD of all age groups (10 with UC, 
238 with CD), 92 of whom were children. Remission 
rate was 49% and 25%, in adult luminal and perianal 
CD respectively. In adults with UC, 50% achieved 
remission and 10% had a partial response. One 
case series reported 21 patients (17 CD, 4 UC) who 
maintained remission for 6 mo[5]. Amongst the adverse 
effects associated with thalidomide and reported in this 
review, the most common was sedation, in 32.3% of all 
patients, followed by peripheral neuropathy in 19.8% 
which was also the main cause of discontinuation[5]. 
Amongst the studies in this review, one high quality 
RCT showed that thalidomide is effective in inducing 
remission in paediatric CD[49]. Based on the evidence 
reviewed and given the limited data available, the 
Authors support the use of Thalidomide in the most 
severe cases of IBD for induction or maintenance of 
remission[5].
Lazzerini et al[49,50] conducted randomized placebo-
controlled trials of thalidomide in both paediatric CD 
and UC (Table 1). In their CD trial, they randomized 
52 children to receive thalidomide or placebo; almost 
all patients had not responded to thiopurines, and 
about 35% had also not responded to biologics. The 
majority of children had luminal disease and few had 
perianal disease. Although no significant response was 
noted at 4 wk, by 8 wk 46% of children treated with 
thalidomide had a reduction in their PCDAI greater than 
75%, compared with 12% amongst patients treated 
with placebo[49]. 
Their UC trial enrolled 26 children with active 
UC who were randomized to receive thalidomide 
or placebo. All patients had active disease despite 
thiopurines, and about 35% had received previous IFX 
treatment. The UC children treated with thalidomide 
achieved higher remission rates at 8 wk (83% vs 19% 
for placebo) than those in the CD trial[50]. 
Both trials showed that thalidomide does not work 
quickly, as there were no significant differences between 
placebo and thalidomide at 4 wk, whereas major 
differences were seen by 8 wk[49,50]. These trials also 
support the use of Thalidomide as a maintenance agent 
in cases of refractory CD or UC, for example patients 
with secondary loss of response to biologics[49,50]. 
Another more recent systematic review conducted by 
Bramuzzo et al[47] analysed 722 papers, including two 
randomized controlled trials and 29 uncontrolled studies 
for a total of 489 patients, 135 (28.4%) of whom were 
children. 
Overall, thalidomide appeared to be a promising 
therapy for IBD: induction of clinical remission was 
achieved in 51.4% of cases, and in 69.3% a clinical 
response was observed in the first months of treatment. 
In almost 50% of the cases in which endoscopy was 
performed, complete MH was observed and a further 
15% of patients showed an improvement in their 
endoscopy score[47]. IBD remission was maintained in 
72.2% after 12 mo and in 54.5% after 2 years[47].
Adverse events leading to drug suspension had a 
cumulative incidence of 19.7/1000 patients-month, 
with neurological symptoms being the main cause[48]. 
This review highlights that thalidomide is an effective 
alternative in patients who fail biologic treatment, 
which is most likely due to the different mechanism of 
action of Thalidomide compared to anti-TNF agents[47]. 
Careful precautions must be taken to avoid its use 
in pregnant women. No case of teratogenicity has 
been observed in 124000 patients enrolled in the 
thalidomide distribution risk management program for 
more than 6 years[49,50]. Other reported side effects of 
thalidomide include peripheral neuropathy (clinical or 
subclinical, primarily with axonal damage) followed 
by sedation, constipation, mood disturbances, skin 
rash, pedal oedema, neutropenia and deep vein 
thrombosis[5,48]. 
STUDIES ON NEW TREATMENTS
New biologics and other agents are being tested 
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investigated is the anti-natural killer group 2 member 
D (NKG2D), which acts by antagonising the human 
immunoglobulin G4 that binds to NKG2D receptors. 
The interaction between intestinal epithelial cells 
and T-cells in the gut mucosa has a key role in T-cell 
regulation. NKG2D receptors are expressed by T 
cells and innate lymphoid cells, and exhibit pro-
inflammatory properties. Upregulated NKG2D ligands 
on epithelial cells in the inflamed tissue of patients with 
IBD may activate the proliferation of several subsets of 
effector T-cells, leading to increased production of pro-
inflammatory cytokines and enhanced cytotoxicity[52]. 
Previous trials have demonstrated an increase in 
effector T cells as well as in the expression of NK 
receptors on T cells in patients with CD[52]. Also, 
neutralising anti-NKG2D antibodies have been shown 
to reduce inflammatory-induced colitis in murine 
models[52]. 
Allez et al[52] performed a randomised, double-
blind, parallel group trial of a single subcutaneous dose 
of 2 mg/kg anti-NKG2D or placebo in 78 adult patients 
with active CD (Table 1).
Change in CDAI from baseline to week 4 was 
the primary end-point, and was not found to differ 
significantly between anti-NKG2D and placebo; 
however, a significant difference was observed by 
week 12 (P ≤ 0.10)[52]. The group of patients who 
hadn’t previously failed biologics and were treated 
with anti-NKG2D (n = 28) showed the most significant 
improvement from week 1 onward. Most adverse 
events were mild (49%) or moderate (43%). No 
antidrug antibodies were detected[52].
Based on the results of this trials, the Authors 
conclude that a single s.c. dose of 2 mg/kg anti-NKG2D 
did not reduce disease activity at week 4, but it showed 
significant response rate at week 12. Therefore, there is 
evidence to consider further investment in anti-NKG2D 
in IBD[52].
DISCUSSION
Though major progress has been achieved in treating 
IBD patients of all ages, there are still significant 
limitations in what is currently available to manage 
this condition. The advent of new biologics and other 
medications targeting pathways previously unexplored 
(e.g., leukocyte trafficking through the gut mucosa) 
has provided clinicians with more hope for patients who 
fail to respond to current treatments. Nevertheless, 
whilst the causative mechanisms underlying IBD are 
not yet fully understood, treatment options can only 
target downstream components of this inflammatory 
chain.
IBD, and CD in particular, are difficult to categorise 
as distinct disease entities, as the spectrum of its 
clinical phenotype is very broad and variable, with mild 
disease responding to standard treatments, and severe 
disease often developing to structuring or penetrating 
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in phase Ⅱ and Ⅲ trials on adult patients with IBD 
and are therefore on the horizon within the field of 
paediatric gastroenterology as well. Examples are 
the IL-23 inhibitor risankizumab and the IL 12- IL 23 
inhibitor ustekinumab. Drug therapies that interfere 
selectively with lymphocyte trafficking are also 
emerging treatment options for UC[11,51]. Etrolizumab 
is a humanized monoclonal antibody against the b7 
integrin subunit that acts by reducing the homing of 
leukocytes to the gut mucosa and the retention of 
lymphocytes in the epithelium[11]. It has recently been 
tested in a phase 2 study showing efficacy in patients 
with moderate to severe UC, compared to placebo[11]. 
Levels of granzyme A (GZMA) and integrin aE (ITGAE) 
mRNAs in colon tissues can identify patients with UC 
who are most likely to benefit from etrolizumab[11] 
(Table 1).
Another agent recently developed is Ozanimod 
(RPC1063), an oral agonist of the sphingosine-1-
phosphate receptor subtypes 1 and 5 that induces 
sequestration of peripheral lymphocytes, and as a 
consequence a decrease in the number of activated 
lymphocytes circulating to the gastrointestinal tract[51]. 
Its agonists induce internalization and degradation of 
the S1P1 receptor, which makes B and T lymphocytes 
incapable of migrating from secondary lymphoid 
organs, with subsequent reduction in circulating 
lymphocytes[51]. Being an oral formulation, Ozanimod 
represents an alternative to infusions of monoclonal 
antibodies for the treatment of UC, with no risk of 
sensitization and formation of antidrug antibodies. On 
the other hand, this product can be less selective than 
monoclonal antibodies, which may expose to adverse 
effects[51].
Sandborn et al[51] performed a double-blind, 
placebo-controlled phase 2 trial of Ozanimod in 197 
adults with moderate-to-severe UC. Clinical remission 
at 8 wk was observed in 16% of the patients who 
received 1 mg of Ozanimod and in 14% of those who 
received 0.5 mg, as compared with 6% of those who 
received placebo (P = 0.048, P = 0.14, respectively) 
(Table 1).
At week 32, the rate of clinical remission was 21% 
in the group that received 1 mg of Ozanimod, 26% in 
the group that received 0.5 mg of Ozanimod, and 6% 
in the group that received placebo; the rate of clinical 
response was 51%, 35%, and 20%, respectively[51]. 
At week 8, absolute lymphocyte counts dropped by 
49% from baseline in the group that received 1 mg of 
Ozanimod and by 32% from baseline in the group that 
received 0.5 mg[51]. The most common adverse events 
overall were anemia and headache[52]. 
From this preliminary trial, the Authors conclude that 
Ozanimod at a daily dose of 1 mg is more effective than 
placebo in inducing clinical remission of UC. However, 
complete assessment of clinical efficacy and safety could 
not be achieved by this trial due to limitations in size 
and duration[51]. Another monoclonal antibody recently 
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phenotypes that require surgery, despite the use of 
multiple treatment escalations[53]. Once significant 
chronic bowel damage occurs in IBD, the chances of 
recovery with medical treatments alone are limited. 
Therefore, the ideal treatment should be offered before 
complications develop[53]. Step-up and top-down 
approaches have been debated for different risk groups 
of children with IBD. The management of paediatric 
IBD has evolved significantly over recent years with 
evidence-based guidelines in place to provide uniform 
and solid guidance in clinical practice. Nevertheless, a 
long-term response is only observed in less than half 
of the patients with CD[3,52]. Although new biologics are 
continuously being developed, primarily monoclonal 
antibodies targeting the trafficking of immune cells, 
we certainly are in need of more therapies with novel 
mechanisms of action[52]. More significant advances 
have been achieved in monitoring drug administration 
and the response to medications, in particular the 
clinical availability of AZA metabolites, IFX and ADA 
trough levels and anti-IFX antibody measurements in 
clinical practice (i.e., TDM). This has allowed a major 
step forward in monitoring and targeting patients’ 
treatments with a more personalised approach.
Despite routine use of solid clinical scores (e.g., 
PCDAI, PUCAI) and biochemical parameters (blood-
based and stool-based), we are currently still de-
pending on invasive reassessments (i.e., endoscopic 
procedures) for an adequate monitoring of the disease 
course. One next goal on the horizon is therefore 
the development of reliable biomarkers to be used 
for prediction of prognostic outcomes in IBD. The 
ability to stratify individual patients’ risk would allow 
clinicians to personalise treatment from disease 
presentation, tailoring more potent drugs (possibly 
in combination) to patients with a high risk of severe 
disease, using more standard options for patients 
who are destined for a milder disease course[53]. This 
individualised approach requires reliable prognostic 
biomarkers and hence major efforts are being made 
in the development of such markers. Risk stratification 
models would allow clinicians to treat patients effectively 
before complications arise, and to optimise majorly the 
management of patients with IBD as improve the cost 
effectiveness of their care[53]. 
CONCLUSION
Our narrative review summarises some of the recent 
advances in treating children with IBD (Table 2). Whilst 
the mechanisms underlying this condition are yet 
to be fully understood, both old and new generation 
treatments can still only target known pathways of 
what is a very complex pathogenesis. A significant 
proportion of children with IBD does not respond to 
currently available treatments, either at diagnosis 
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Table 2  Summary and take home messages
1. The pathogenesis of IBD is not completely understood yet, and all therapies currently available are aimed at downstream steps of the complex 
inflammatory process. Specific targets when treating children with IBD are achieving satisfactory growth and nutritional status.
2. Paediatric pharmacometric approaches are increasingly applied to drugs already in use but that remain unlicensed and off-label in children due to 
missing information on age appropriate dosing, efficacy and safety.
3. Corticosteroids can be used to induce remission in CD (when exclusive enteral nutrition is not possible) and are first-line therapy for induction of 
remission in UC, particularly in case of non-response to 5-ASA or with severe presentation.
4. One of the targets of current research is to customise therapy to a patient’s predictive biomarker profile in order to personalise treatments and to 
maximise response.
5. 5-ASA are used in induction and maintenance of remission in UC. They are not recommended in CD except from post-operative maintenance of 
remission.
6. Thiopurines include AZA and 6-MP and are steroid sparing agents. They are effective in maintaining disease remission in patients with CD and 
UC as well as post-surgical remission in CD. The use of TPMT activity and 6-TGN level measurements helps avoiding nearly a quarter of episodes of 
myelosuppression as well as to monitor non-compliance, under-dosing, drug-resistance or refractory state.
7. An increase in mean 6-TGN blood level has been reported in patients on 6-MP or AZA co-treated with 5-ASA, with a higher rate of myelotoxicity in 
respect to patients treated with the thiopurine alone.
8.  MTX is effective in 50%-80% of the children who fail to respond or are intolerant to thiopurines. It is particularly suitable to patients who have 
coexistent inflammatory arthritis.
9. In CD, anti-TNF agents are used to treat moderate to severe disease with inadequate response, or contraindication to, or intolerance to, conventional 
therapy including corticosteroids and immunomodulators. They are also indicated in children with active perianal fistulising disease. Therapeutic drug 
monitoring of IFX has improved response rates and is increasingly used in clinical practice as a tool for the management of secondary failure to IFX.
10. ADA is a fully human IgG1k monoclonal antibody, which represents a treatment option in patients who have lost response or are intolerant to IFX. 
ADA achieves remission rates of 45% at 1 yr in anti-TNF naïve children and is effective in nearly 2/3 of patients with IFX failure.
11. Vedolizumab is an anti-integrin therapy which inhibits the migration of intestinal T lymphocytes. The mechanism of action of Vedolizumab is 
restricted to the GI tract, mitigating the risks of systemic immunosuppression such as infections and malignancies. The clinical response rate for 
induction with vedolizumab is 50% in UC patients. Vedolizumab is approved for treatment of CD and UC in adults and there is increasing off-label use 
in children.
12. Thalidomide is an immunosuppressant drug used infrequently off-label in the treatment of refractory CD and UC. Induction of remission is achieved 
in aroud 50% cases and clinical response in 70%.
13. Drug therapies that interfere selectively with lymphocyte trafficking (e.g., etrolizumab, ozanimod) are emerging treatment options for UC.
UC: Ulcerative colitis; IBD: Inflammatory bowel disease; ADA: Adalimumab; IFX: Infliximab; TPMT: Thiopurine methyl transferase; 5-ASA: 
Aminosalicylates; CD: Crohn’s disease; 6-MP: 6-mercaptopurine; AZA: Azathioprine; MTX: Methotrexate; GI: Gastrointestinal.
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or during disease course, therefore new treatment 
options are urgently needed. Major advances have 
been achieved in monitoring the individual metabolism, 
toxicity and response to treatments in IBD. Amongst 
the priorities in current research is the development 
of reliable prognostic biomarkers, an essential step 
towards the personalised treatment of patients with 
IBD.
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